Literature DB >> 16357711

Erythema elevatum diutinum in the setting of connective tissue disease and chronic bacterial infection.

Carol M Woody1, Joshua E Lane, Loretta S Davis.   

Abstract

Erythema elevatum diutinum (EED) is a rare and chronic cutaneous leukocytoclastic vasculitis. It is predominantly seen on the extensor surfaces of the extremities. Although a specific cause is largely unknown, EED has been noted to occur in association with a wide variety of diseases. A 28-year-old man with systemic lupus erythematosus (SLE) and a 53-year-old woman with an overlap syndrome of rheumatoid arthritis and polymyositis are presented. Both patients developed EED in the setting of chronic recurrent bacterial infections. Patients with a connective tissue disease are at increased risk for such infections secondary to immunosuppression, either from the disease itself or secondary to immunosuppressive therapy. EED has been independently reported to occur in the setting of connective tissue disease as well as in the setting of chronic infection. Our patients had both of these underlying conditions, which are known to predispose patients to immune complex-mediated vasculitides, in this case EED. One patient's EED responded to treatment of the SLE and the other improved, as has been previously reported with dapsone.

Entities:  

Mesh:

Year:  2005        PMID: 16357711     DOI: 10.1097/01.rhu.0000158540.57267.34

Source DB:  PubMed          Journal:  J Clin Rheumatol        ISSN: 1076-1608            Impact factor:   3.517


  2 in total

1.  The development of erythema elevatum diutinum in a patient with juvenile idiopathic arthritis under treatment with abatacept.

Authors:  Andrea Golmia; Beni Grinblat; Eduardo Finger; Claudia Klieman; Fernanda Assir; Morton Scheinberg
Journal:  Clin Rheumatol       Date:  2007-10-12       Impact factor: 2.980

2.  Erythema elevatum diutinum in systemic lupus erythematosus.

Authors:  Yung Chan; Chi Chiu Mok; William Yuk Ming Tang
Journal:  Rheumatol Int       Date:  2010-07-23       Impact factor: 2.631

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.